Arthritis & rheumatology (Hoboken, N.J.) · 2026
Dual Effects of β-TrCP2 Deletion in Bone Homeostasis: Suppression of Osteoclastogenesis and Enhancement of Osteoblast Activity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Woo Jung, Han Sora, Ka Hye In, Lee Sun Young, Kim Jiwon, Joo Hyunjeong, Soh Sujung, Oh Gaeun, Yoo Kyung Hyun, Han Seung Hyun, Kwon Yeongkag, Lee Choogon, Park-Min Kyung-Hyun, Mun Se Hwan, Yang Young
Аннотация
OBJECTIVES: To elucidate role of beta-transducin repeat-containing protein 2 (β-TrCP2) in bone homeostasis for its potential as a therapeutic target for osteoporosis.
METHODS: The role of β-TrCP2 in bone phenotypes was investigated using systemic β-TrCP1KO and β-TrCP2KO mice, along with myeloid-specific conditional β-TrCP2KO (β-TrCP2ΔM) mice. Bone microarchitecture was assessed by micro-computed tomography, and osteoclast and osteoblast parameters by histomorphometry. Osteoclast resorptive activity was evaluated using dentine slice pit assays. Mechanisms regulating osteoclastogenesis were investigated by RNA sequencing, RT-qPCR, immunoprecipitation, and immunoblotting. Bone formation and injury-induced repair were assessed by dynamic histomorphometry and drill-hole defect model. Therapeutic potential was evaluated in ovariectomized WT and β-TrCP2KO mice.
RESULTS: β-TrCP2 KO and β-TrCP2ΔM mice exhibited the increased bone mass and reduced osteoclast numbers compared to WT, but not β-TrCP1 KO mice. The β-TrCP2 KO bone marrow-derived myeloid cells were treated with RANKL. The activity and markers of osteoclast were decreased and interferon-β (IFN-β) was increased. Mechanistically, β-TrCP2-mediated IKKε ubiquitination and degradation is a critical event for enhancing IFN-β expression via IRF3 by RANKL or LPS stimulation. β-TrCP2 KO mice showed increased osteoblast differentiation and bone formation through β-catenin stabilization and upregulation of osteogenic genes. In post-osteoporosis induction therapeutic ovariectomized model, β-TrCP2 KO mice were protected from bone loss through both decreased osteoclast formation and enhanced osteoblast activity.
CONCLUSION: β-TrCP2 regulates osteoclast formation by modulating IKKε-IRF3-IFN-β and NF-κB signaling pathway and influences osteoblast activity by β-catenin accumulation. This study suggests that β-TrCP2 has potential as a novel therapeutic target for osteoporosis.
METHODS: The role of β-TrCP2 in bone phenotypes was investigated using systemic β-TrCP1KO and β-TrCP2KO mice, along with myeloid-specific conditional β-TrCP2KO (β-TrCP2ΔM) mice. Bone microarchitecture was assessed by micro-computed tomography, and osteoclast and osteoblast parameters by histomorphometry. Osteoclast resorptive activity was evaluated using dentine slice pit assays. Mechanisms regulating osteoclastogenesis were investigated by RNA sequencing, RT-qPCR, immunoprecipitation, and immunoblotting. Bone formation and injury-induced repair were assessed by dynamic histomorphometry and drill-hole defect model. Therapeutic potential was evaluated in ovariectomized WT and β-TrCP2KO mice.
RESULTS: β-TrCP2 KO and β-TrCP2ΔM mice exhibited the increased bone mass and reduced osteoclast numbers compared to WT, but not β-TrCP1 KO mice. The β-TrCP2 KO bone marrow-derived myeloid cells were treated with RANKL. The activity and markers of osteoclast were decreased and interferon-β (IFN-β) was increased. Mechanistically, β-TrCP2-mediated IKKε ubiquitination and degradation is a critical event for enhancing IFN-β expression via IRF3 by RANKL or LPS stimulation. β-TrCP2 KO mice showed increased osteoblast differentiation and bone formation through β-catenin stabilization and upregulation of osteogenic genes. In post-osteoporosis induction therapeutic ovariectomized model, β-TrCP2 KO mice were protected from bone loss through both decreased osteoclast formation and enhanced osteoblast activity.
CONCLUSION: β-TrCP2 regulates osteoclast formation by modulating IKKε-IRF3-IFN-β and NF-κB signaling pathway and influences osteoblast activity by β-catenin accumulation. This study suggests that β-TrCP2 has potential as a novel therapeutic target for osteoporosis.